Transfer Of Value Disclosure
FINANCIAL INFORMATION:
The following describes the funding received from non-NHS organisations to support programmes of work that aim to improve the health and care system in the North East and North Cumbria:
| Organisations Involved | Start Date | End Date | Monetary Value | Reason for Benefit |
| Chiesi Farmaceutici and AHSN NENC | 01/02/2022 | 16/05/2022 | £5,000.00 | To develop the Pharm outcomes template for the Tees Valley Inhaler Project |
| OrionPharma (UK) Ltd and AHSN NENC | 01/02/2022 | 16/05/2022 | £5,400.00 | To develop the Pharm outcomes template for the Tees Valley Inhaler Project |
| AstraZeneca PLC and AHSN NENC | 01/02/2022 | 16/05/2022 | £26,400.00 | To deliver the pilot programme of work for the Tees Valley Inhaler project |
| GlaxoSmithKline and AHSN NENC | 01/02/2022 | 16/05/2022 | £5,400.00 | To develop the Pharm outcomes template as part of the Tees Valley Inhaler project |
| Sanofi | 31/03/2022 | 30/09/2023 | £37,479.28 | JWA to facilitate earlier diagnosis of Fabry, Pompe and Gaucher diseases through the use of disease prediction models using real-work data from Primary Care records (CDRC – rare diseases) |
| Sanofi | 20/10/2022 | 20/10/2022 | £400.00 | Sponsorship to part fund the Northern Lipids Forum Event held on the 20th October 2022 |
| Amgen Ltd | 20/10/2022 | 20/10/2022 | £400.00 | Sponsorship to part fund the Northern Lipids Forum Event held on the 20th October 2022 |
| Novartis Pharmaceuticals UK Ltd | 20/10/2022 | 20/10/2022 | £400.00 | Sponsorship to part fund the Northern Lipids Forum Event held on the 20th October 2022 |
| Daiichi Sankyo | 20/10/2022 | 20/10/2022 | £400.00 | Sponsorship to part fund the Northern Lipids Forum Event held on the 20th October 2022 |
| Amarin UK Ltd | 20/10/2022 | 20/10/2022 | £400.00 | Sponsorship to part fund the Northern Lipids Forum Event held on the 20th October 2022 |
| Sanofi (registered name Aventis Pharma Ltd) | 18/11/2022 | 31/03/2023 | £768.00 | Reimbursement costs for a guest speaker at a Sanofi event |
| Novartis Pharmaceuticals | 23/12/2022 | 23/12/2023 | £150,000 | Undertake medical education activities around holistic lipid management and prevention of CVD |
| Boehringer Ingleheim | 01/02/2022 | 30/09/2023 | 3000 Contracts | Grant/donation towards education and service development in support of Improving outcomes for Respiratory patients, Tees Valley inhaler project |
| Novartis Pharmaceuticals UK Limited | 20/10/2021 | 31/03/2024 | £111,294 | Support the implementation of the NHSE-Novartis collaboration project as part of the AHSN Network’s national lipid optimisation programme |
| Novartis Pharmaceuticals UK Limited | 01/04/2023 | 31/03/2024 | £198,000 | Sustain secondary care and primary care clinical roles, develop primary care lipid hub and embed projects supported by AHSN NENC CVD team |
| Novartis Pharmaceuticals UK Limited | 27/09/2022 | 26/04/2024 | £135,024 | Promote the use of the nationally endorsed lipid management pathway and service transformation work and promote adoption of best practice |
| Amarin UK Limited | 17/07/2023 | 19/10/2023 | £650 | To support the annual Northern Lipid Forum |
| Amarin UK Limited, South Tyneside and Sunderland NHS FT and AHSN NENC | 01/10/2023 | 30/09/2024 | £38,200 | The project is to secure and expand the Lipid Optimisation clinic at STSFT and take a holistic approach to patient care, including provision of dietician support for patients. |
| Daiichi Sankyo | 15/06/2023 | 30/11/2023 | £650 | To support the annual Northern Lipid Forum |
| Amgen | 16/06/2023 | 30/11/2023 | £650 | To support the annual Northern Lipid Forum |
| Novartis | 17/07/2023 | 30/11/2023 | £650 | To support the annual Northern Lipid Forum |
| Sanofi | 21/06/2023 | 30/11/2023 | £650 | To support the annual Northern Lipid Forum |
| Aventis Pharma Limited t/a Sanofi and AHSN NENC (now HI NENC) | 31/03/2022 | 31/12/2024 | £12,000 | To programme the disease prediction models into a CDRC precision tool which will sit within GP clinical systems in the NENC region |
| AHSN NENC (now HI NENC) and Amgen | 31/01/2023 | 31/01/2025 | £25,000 | Project management support from Alison Crocker and Mark Harris to improve the identification and treatment of patients with FH and the secondary prevention of patients with high risk cardio vascular disease in primary care in relation to Lipid Optimisation |
| AHSN NENC (now HI NENC) and Astra Zeneca | 07/07/2022 | 31/07/2024 | £38,725 | CardioRenal Optimisation secondment of Christopher Gray |